Margarida Maia, PhD,  science writer—

Margarida is a biochemist (University of Porto, Portugal) with a PhD in biomedical sciences (VIB and KULeuven, Belgium). Her main interest is science communication. She is also passionate about design and the dialogue between art and science.

Articles by Margarida Maia

HAE therapy ADX-324 hits Phase 3 milestone with first treatment

The first adult participant with hereditary angioedema (HAE) has been dosed in STOP-HAE, a Phase 3 clinical trial evaluating the efficacy of ADARx Pharmaceuticals’ investigational therapy ADX-324. Designed as a long-acting preventive treatment, ADX-324 aims to reduce the frequency of swelling attacks while requiring fewer injections. The…

Biocryst to acquire Astria, getting experimental navenibart for HAE

Biocryst Pharmaceuticals is preparing to acquire Astria Therapeutics, and with it navenibart, a still-experimental, long-acting prophylactic (preventive) treatment that could improve care for people with hereditary angioedema (HAE) by reducing how often patients need injections. Navenibart is now in Phase 3 clinical testing, after earlier data…

Haloperidol causes rare case of tongue angioedema: Report

Haloperidol, an antipsychotic medication commonly used to treat schizophrenia and severe agitation, was behind a rare case of angioedema of the tongue — a sudden, potentially life-threatening swelling — for a man in Tunisia, as detailed a case report. Although angioedema can occur as an allergic reaction or as…

FDA approves Andembry as preventive treatment for HAE

The U.S. Food and Drug Administration (FDA) has approved Andembry (garadacimab-gxii) to prevent swelling attacks caused by hereditary angioedema (HAE) in adults and adolescents, ages 12 and older, adding the U.S. to the countries where the medication is available. Developed by CSL Behring, it’s the only treatment…

ED visits help most patients with drug-induced angioedema: Study

More than half of individuals admitted to an emergency department, or ED, for drug-induced nonallergic angioedema — with nearly all of these patients experiencing swelling as a side effect of medications known as angiotensin-converting enzyme inhibitors, or ACEIs — showed improvement, with most staying briefly and few returning…

Sebetralstat provides early, fast relief for HAE attacks: Data

Sebetralstat, an oral small molecule being developed by Kalvista Pharmaceuticals, provided adults and adolescents with hereditary angioedema (HAE) with early on-demand treatment for swelling attacks and offered fast symptom relief, even when swelling affected the larynx (voice box). That’s according to interim data from KONFIDENT-S (NCT05505916),…